Biogen Idec Expects Tysabri-Related Charges Up To $100 Mil. In 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
First quarter charges related to the withdrawn multiple sclerosis therapy totaled $36 mil. Inventory charges are expected in the second quarter as the company completes the natalizumab production cycle; idle capacity charges totaling $20 mil.-$30 mil. are likely in the latter half of the year.
You may also be interested in...
Biogen Tysabri Facility Will Shift To Avastin Production Under New Owner
Genentech agreed to pay Biogen $408.1 mil. for its southern California Tysabri facility to add capacity for Avastin. The facility was undergoing validation; Biogen expected to begin selling the multiple sclerosis therapy out of the facility by 2006.
Biogen Tysabri Facility Will Shift To Avastin Production Under New Owner
Genentech agreed to pay Biogen $408.1 mil. for its southern California Tysabri facility to add capacity for Avastin. The facility was undergoing validation; Biogen expected to begin selling the multiple sclerosis therapy out of the facility by 2006.
SEC Opens Tysabri Investigation
The Securities & Exchange Commission has opened an investigation into the marketing suspension of Biogen Idec/Elan's multiple sclerosis therapy Tysabri (natalizumab)